Why the study?
The rapid expansion of indications for glucagon-like peptide-1-based therapies has exposed real-world challenges, including a substantial burden of adverse events, emerging long-term safety signals, and inequities in access, creating a need for graded clinical recommendations.
Provides 77 evidence-based, graded clinical recommendations for organ-directed safety monitoring and management of patients prescribed GLP-1-based therapies across cardiometabolic indications.
Answers are grounded in this paper and cite their sources.
Robust evidence supports GLP-1 therapies across cardiometabolic conditions; leaves open optimal strategies for real-world implementation challenges.
Glucagon-Like Peptide-1–based therapies, including selective and dual receptor agonists, have transformed cardiometabolic medicine. Robust evidence now supports their use in type 2 diabetes mellitus, obesity, cardiovascular prevention, heart failure with preserved ejection fraction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction-associated steatotic liver disease. The rapid expansion of indications has also exposed real-world challenges, including a substantial burden of adverse events, emerging long-term safety signals, and inequities in access. This review addresses the key clinical questions encountered when prescribing these agents and provide graded recommendations for specialized and general practice, integrating Turkish national real-world data with international trial evidence. The review covers organ-directed safety and monitoring, namely gastrointestinal adverse events, pancreatic and hepatobiliary safety, body composition including muscle and bone, ophthalmic considerations, and thyroid safety. Further issues such as reproductive health, cancer risk, treatment duration and interruption, perioperative and post-bariatric management, and care in special populations will be covered in the next issue. Landmark randomized controlled trials, meta-analyses, regulatory documents, expert consensus statements, and national registry data published through May 2026 were utilized. Recommendations follow a modified American Association of Clinical Endocrinologists grading framework (grade A to D) with a directional indicator (↑ recommended, ↓ not recommended). Universally accepted safety, ethical, or regulatory practices not amenable to formal grading are designated Good Practice Statements. This review provides 77 recommendations across 20 clinical questions in 5 sections. Each part is numbered independently and can be read on its own. Cite this article as: S.nmez A, Kiyici S, Koca AO, Hepşen S, Haymana C, Bayram F. Glucagon-like peptide-1–based therapies in clinical practice: key questions, controversies, and evidence-based recommendations. Endocrinol Res Pract. Published online November 3, 2026. doi: 10.5152/erp.2026.26929.
No takes yet. Share an insight, caveat, or question.
Sönmez et al. (2026) conducted a review in Type 2 diabetes mellitus, obesity, cardiovascular prevention, heart failure with preserved ejection fraction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction-associated steatotic liver disease. Glucagon-Like Peptide-1–based therapies (selective and dual receptor agonists) was evaluated on Organ-directed safety and monitoring (gastrointestinal, pancreatic, hepatobiliary, body composition, ophthalmic, and thyroid safety). GLP-1-based therapy prescribing is guided by 77 graded clinical recommendations across 20 clinical questions in 5 sections regarding organ-directed safety and monitoring.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: